| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Furniture and equipment, net | 991 | |||
| Right-of-use assets | 1,574 | |||
| Inventory, long-term | 5,910 | |||
| Goodwill | 545 | |||
| Equity interest | 15,000 | |||
| Total non-current assets | 24,020 | |||
| Tax incentive receivable | 4,061 | |||
| Prepaid expenses | 11,432 | |||
| Other current assets | 3,872 | |||
| Equity interest receivable | 8,612 | |||
| Cash and cash equivalents | 438,016 | |||
| Accounts receivable, net | 82,858 | |||
| Total current assets | 548,851 | |||
| Total assets | 572,871 | |||
| Accrued expenses | 43,328 | |||
| Revenue interest purchase security agreement | 0 | |||
| Taxes payable | 0 | |||
| Other current liabilities | 374 | |||
| Current operating lease liabilities | 1,014 | |||
| Royalties payable | 3,088 | |||
| Accounts payable | 3,434 | |||
| Total current liabilities | 51,238 | |||
| Revenue interest purchase security agreement | 0 | |||
| Non-current operating lease liabilities | 926 | |||
| Term loan | 242,434 | |||
| Total non-current liabilities | 243,360 | |||
| Total liabilities | 294,598 | |||
| Ordinary shares held in treasury | 964 | |||
| Accumulated deficit | -567,101 | |||
| Ordinary 0.05 par value shares 703,189,462 and 703,189,462 issued, and 687,930,486 and 677,008,254 outstanding, at june 30, 2025 and december 31, 2024, respectively | 45,021 | |||
| Additional paid-in capital | 805,918 | |||
| Accumulated other comprehensive loss | -4,601 | |||
| Total shareholders' equity | 278,273 | |||
| Total liabilities and shareholders' equity | 572,871 | |||
Verona Pharma plc (VRNA)
Verona Pharma plc (VRNA)